These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 19275632)

  • 41. Amyloid-beta vaccination: testing the amyloid hypothesis?: heads we win, tails you lose!
    Lee HG; Zhu X; Nunomura A; Perry G; Smith MA
    Am J Pathol; 2006 Sep; 169(3):738-9. PubMed ID: 16936250
    [No Abstract]   [Full Text] [Related]  

  • 42. Improved synaptic and cognitive function in aged 3 × Tg-AD mice with reduced amyloid-β after immunotherapy with a novel recombinant 6Aβ15-TF chimeric vaccine.
    Yu YZ; Li QL; Wang HC; Liu S; Pang XB; Xu Q; Zhou XW; Huang PT
    Clin Immunol; 2018 Aug; 193():12-23. PubMed ID: 29803820
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Current status of Alzheimer's disease immunotherapy and pharmacologic effect of BAN2401.].
    Araki S
    Nihon Yakurigaku Zasshi; 2010 Jul; 136(1):21-5. PubMed ID: 20628209
    [No Abstract]   [Full Text] [Related]  

  • 44. A Novel scFv Anti-Aβ Antibody Reduces Pathological Impairments in APP/PS1 Transgenic Mice via Modulation of Inflammatory Cytokines and Aβ-related Enzymes.
    Hu M; Zhang J; Yang J; Cao Y; Qi J
    J Mol Neurosci; 2018 Sep; 66(1):1-9. PubMed ID: 30062438
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [The role of beta-amyloid peptide in pathogenesis and immunotherapy of Alzheimer's diseases].
    Yu SN; Liu LY; Liang P
    Zhonghua Bing Li Xue Za Zhi; 2005 Feb; 34(2):113-4. PubMed ID: 15842811
    [No Abstract]   [Full Text] [Related]  

  • 46. Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials.
    Menéndez-González M; Pérez-Piñera P; Martínez-Rivera M; Muñiz AL; Vega JA
    Curr Pharm Des; 2011; 17(5):508-20. PubMed ID: 21375481
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Aβ immunotherapy for Alzheimer's disease: where are we?
    Güell-Bosch J; Montoliu-Gaya L; Esquerda-Canals G; Villegas S
    Neurodegener Dis Manag; 2016 Jun; 6(3):179-81. PubMed ID: 27230296
    [No Abstract]   [Full Text] [Related]  

  • 48. Impact of amyloid β aggregate maturation on antibody treatment in APP23 mice.
    Balakrishnan K; Rijal Upadhaya A; Steinmetz J; Reichwald J; Abramowski D; Fändrich M; Kumar S; Yamaguchi H; Walter J; Staufenbiel M; Thal DR
    Acta Neuropathol Commun; 2015 Jul; 3():41. PubMed ID: 26141728
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunotherapy for Alzheimer's disease.
    Steinitz M
    Immunotherapy; 2009 May; 1(3):461-9. PubMed ID: 20635962
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities.
    Zago W; Schroeter S; Guido T; Khan K; Seubert P; Yednock T; Schenk D; Gregg KM; Games D; Bard F; Kinney GG
    Alzheimers Dement; 2013 Oct; 9(5 Suppl):S105-15. PubMed ID: 23583235
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Translating research on brain aging into public health: a new type of immunotherapy for Alzheimer's disease.
    Lannfelt L; Pettersson FE; Nilsson LN
    Nutr Rev; 2010 Dec; 68 Suppl 2():S128-34. PubMed ID: 21091946
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Immunotherapy for Alzheimer's disease targeting Aβ].
    Tabira T
    Nihon Rinsho; 2016 Mar; 74(3):423-6. PubMed ID: 27025080
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Transgenic expression of β1 antibody in brain neurons impairs age-dependent amyloid deposition in APP23 mice.
    Paganetti P; Reichwald J; Bleckmann D; Abramowski D; Ammaturo D; Barske C; Danner S; Molinari M; Müller M; Papin S; Rabe S; Schmid P; Staufenbiel M
    Neurobiol Aging; 2013 Dec; 34(12):2866-78. PubMed ID: 23870837
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lack of P-glycoprotein Results in Impairment of Removal of Beta-Amyloid and Increased Intraparenchymal Cerebral Amyloid Angiopathy after Active Immunization in a Transgenic Mouse Model of Alzheimer's Disease.
    Bruckmann S; Brenn A; Grube M; Niedrig K; Holtfreter S; von Bohlen und Halbach O; Groschup M; Keller M; Vogelgesang S
    Curr Alzheimer Res; 2017; 14(6):656-667. PubMed ID: 27915995
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical immunologic approaches for the treatment of Alzheimer's disease.
    Solomon B
    Expert Opin Investig Drugs; 2007 Jun; 16(6):819-28. PubMed ID: 17501694
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Conformation-specific antibodies to target amyloid β oligomers and their application to immunotherapy for Alzheimer's disease.
    Murakami K
    Biosci Biotechnol Biochem; 2014; 78(8):1293-305. PubMed ID: 25130729
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Beta-amyloidbased immunotherapy as a treatment of Alzheimers disease.
    Solomon B
    Drugs Today (Barc); 2007 May; 43(5):333-42. PubMed ID: 17724499
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Aβ-Immunotherapeutic strategies: a wide range of approaches for Alzheimer's disease treatment.
    Montoliu-Gaya L; Villegas S
    Expert Rev Mol Med; 2016 Jun; 18():e13. PubMed ID: 27357999
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Amyloid beta peptide immunotherapy in Alzheimer disease.
    Delrieu J; Ousset PJ; Voisin T; Vellas B
    Rev Neurol (Paris); 2014 Dec; 170(12):739-48. PubMed ID: 25459121
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 4Aβ1-15-Derived Monoclonal Antibody Reduces More Aβ Burdens and Neuroinflammation than Homologous Vaccine in APP/PS1 Mice.
    Zhang Y; Zou J; Yang J; Yao Z
    Curr Alzheimer Res; 2015; 12(4):384-97. PubMed ID: 25817256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.